


PROPOSED AMENDMENTS TO THE CLAIMS IN APPLICATION 10/642,440

A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listing of claims in this patent application.

Claim 1 (Currently Amended): A compound having a structure of including resolved enantiomers, solvates, diastereomers and pharmaceutically acceptable salts thereof, said compound comprising Formula I:



or resolved enantiomers, diastereomers or pharmaceutically acceptable salts thereof: wherein an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R³ groups;

X is N;

R¹ is a substituted or unsubstituted[[],] monoecyclic or bicyclic, aryl moiety phenyl;

R² is H or a substituted or unsubstituted C₁₋₈ alkyl;


R³ is hydrogen, halogen, cyano, nitro[[],] C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heteroecyethyl, heteroecyethylalkyl, NR⁴SO₂R⁵-SO₂NR⁶R⁴, C(O)R⁶, C(O)OR⁶[[],] -OC(O)R⁶, -NR⁴C(O)OR⁵, NR⁴C(O)R⁶, C(O)NR⁴R⁶[[],] -NR⁴R⁶, -NR⁴C(O)NR⁴R⁶[[],] or -OR⁶, -S(O)R⁵, -SO₂R⁵[[],] where each of the above alkyl, alkenyl, alkynyl, cycloalkyl[[],] and aryl[[],] heteroaryl and heteroecyethyl portion of R³ is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, NR⁴SO₂R⁵, SO₂NR⁶R⁴, C(O)R⁶, C(O)OR⁶[[],] -OC(O)R⁶, -NR⁴C(O)OR⁵, NR⁴C(O)CR⁶, C(O)NR⁴R⁶[[],] -NR⁴R⁶, -NR⁴C(O)NR⁴R⁶, -NR⁴C(NCN)NR⁴R⁶[[],] -OR⁶, S(O)R⁵, -SO₂R⁵[[],] aryl[[],] and arylalkyl, heteroaryl, heteroarylalkyl, heteroecyethyl, and heteroecyethylalkyl;

A is -(U)_nZ, where

n is 0;

Application 10/642,440

Z is



where W and V are selected independently from CR^7R^8 , CR^8R^9 , O, $[-S]S$, SO, SO_2 , provided

if W is O, $[-S]S$, SO, SO_2 , then V is CR^8R^9 , and provided that R^6 directly bonded to Z is not H;

Z includes one or more R^8 or R^9 groups, wherein said R^8 and R^9 groups may be bonded to the same or different atoms;

R^4 is H or C_{1-6} alkyl;

R^5 is trifluoromethyl, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl and heterocyclylalkyl is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, OR^6 , NR^4R^6 , trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;

R^6 , R^8 and R^9 are independently selected from hydrogen, trifluoromethyl, C_1-C_{10} alkyl, $(CH_2)_{0-4}C_3-C_{10}$ cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, OR^6 , NR^6R^8 , trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;

R^7 is hydrogen, halogen, cyano, nitro, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, $-NR^4SO_2R^5$, $-SO_2NR^6R^4$, $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^4C(O)OR^5$, $-NR^4C(O)R^6$, $-C(O)NR^4R^6$, $-NR^4R^6$, $-NR^4C(O)NR^4R^6$, $-OR^6$, $-S(O)R^5$, $-SO_2R^5$, where each of the above alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion of R^3 is

Application 10/642,440

optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, $-\text{NR}^4\text{SO}_2\text{R}^5$, $-\text{SO}_2\text{NR}^6\text{R}^4$, $-\text{C}(\text{O})\text{R}^6$, $-\text{C}(\text{O})\text{OR}^6$, $-\text{OC}(\text{O})\text{R}^6$, $-\text{NR}^4\text{C}(\text{O})\text{OR}^5$, $-\text{NR}^4\text{C}(\text{O})\text{CR}^6$, $-\text{C}(\text{O})\text{NR}^4\text{R}^6$, $-\text{NR}^4\text{R}^6$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^4\text{R}^6$, $-\text{NR}^4\text{C}(\text{NCN})\text{NR}^4\text{R}^6$, $-\text{OR}^6$, $-\text{S}(\text{O})\text{R}^5$, $-\text{SO}_2\text{R}^5$, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;

an R^4 group and an R^6 group may be independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO₂ and NR⁶ where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR⁸, NR⁶R⁸, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms;

an R^6 group and an R^8 group may be independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO₂ and NR⁶ where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR⁸, NR⁶R⁸, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms;

an R^7 group and an R^8 group may be independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO₂ and NR⁶ where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR⁸, NR⁶R⁸, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms; and

an R^8 group and an R^9 group may be independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO₂ and NR⁶ where each ring carbon may be optionally substituted with

Application 10/642,440

one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR⁸, NR⁶R⁸, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.

Claim 2: (Canceled).


Claim 3 (Currently Amended): The compound of claim 1, wherein [[a]] the A group is bonded to at least one of the carbons at the 6 or 7 position of the bicyclic ring.

Claim 4 (Previously Amended): The compound of claim 1, wherein R² is hydrogen, and R³ is hydrogen or OR⁶.

Claim 5 (Previously Amended): The compound of claim 3, wherein R³ is hydrogen or OR⁶.


Claim 6 (Original Claim): The compound of claim 1, wherein R² is hydrogen.

Claim 7 (Previously Amended): The compound of claim 1, wherein Z is



and W is O.

Application 10/642,440

Claim 8 (Previously Amended): The compound of claim 5, wherein Z is

and W is O.

Claim 9 (Original Claim): The compound of claim 1, wherein the R⁴ group and the R⁶ group are independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO₂ and NR⁶ where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR⁸, NR⁶R⁸, heteroaryl, arylalkyl, heteroarylalkyl, heterocycl, and heterocyclalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.**Claim 10 (Original Claim):** The compound of claim 1, wherein the R⁶ group and the R⁸ group are independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO₂ and NR⁶ where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR⁸, NR⁶R⁸, heteroaryl, arylalkyl, heteroarylalkyl, heterocycl, and heterocyclalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.**Claim 11 (Previously Amended):** The compound of claim 1, wherein the R⁷ group and the R⁸ group are independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO₂ and NR⁶ where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido,

Application 10/642,440

aryl, OR⁸, NR⁶R⁸, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.

Claim 12 (Original Claim): The compound of claim 1, wherein the R⁸ group and the R⁹ group are independently joined to complete a 3 to 10 membered cyclic ring optionally containing additional heteroatoms selected from the group consisting of O, S, SO, SO₂ and NR⁶ where each ring carbon may be optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR⁸, NR⁶R⁸, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; provided said ring does not contain two adjacent O or two adjacent S atoms.

Claim 13 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 1 to said mammal.

Claim 14 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 2 to said mammal.

Claim 15 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 3 to said mammal.

Claim 16 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus

Application 10/642,440

and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 4 to said mammal.

Claim 17 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 5 to said mammal.

Claim 18 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 6 to said mammal.

Claim 19 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 7 to said mammal.

Claim 20 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 8 to said mammal.

Claim 21 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 9 to said mammal.


Application 10/642,440

Claim 22 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 10 to said mammal.

Claim 23 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 11 to said mammal.

Claim 24 (Currently Amended): A method of treating hyperproliferative diseases inflammation and cancer of the colon, ovary, bladder, breast, stomach, esophagus, lung, uterus and prostate in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 12 to said mammal.

Claim 25 (Previously Presented): The compound of claim 1, wherein R¹ is selected from the structures:



Application 10/642,440

Claim 26 (Previously Presented): The compound of claim 7, wherein R⁶ is an optionally substituted alkyl or cycloalkyl.


Claim 27 (Previously Presented): The compound of claim 26, wherein R⁶ is methyl, ethyl, CH₂CF₃, CH₂CH₂OH, or cyclopropyl.

Claim 28 (Previously Presented): The compound of claim 26, wherein R⁸ and R⁹ are independently an optionally substituted alkyl.




Claim 29 (Previously Presented): The compound of claim 28, wherein R⁸ and R⁹ are independently CH₂OH, CH₂NMe₂ or CH₂O-t-butyl.

Claim 30 (Previously Presented): The compound of claim 26, wherein R⁸ and R⁹ together with the atoms to which they are attached form an optionally substituted heterocyclic ring.

Claim 31 (Previously Amended): The compound of claim 7, wherein Z is selected from the structures:



Application 10/642,440

**Claim 32 (Previously Presented):** The compound of claim 1, wherein Z is**Claim 33 (Previously Presented):** The compound of claim 32, wherein R⁶ is an optionally substituted alkyl.**Claim 34 (Previously Amended):** The compound of claim 33, wherein R⁶ is methyl.**Claim 35 (Previously Presented):** The compound of claim 34, wherein Z is**Claim 36 (Previously Amended):** The compound of claim 1, selected from:

N4-[3-Chloro-4-(3-fluorobenzyl)-phenyl]-N6-(3-methyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine;

N4-[3-Chloro-4-(3-fluorobenzyl)-phenyl]-N6-(3-ethyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine;

(2-{4-[3-Chloro-4-(3-fluorobenzyl)-phenylamino]-quinazolin-6-ylimino}-3-methyl-oxazolidin-5-yl)-methanol;

2-(2-{4-[3-Chloro-4-(3-fluorobenzyl)-phenylamino]-quinazolin-6-ylimino}-oxazolidin-3-yl)-ethanol;

Application 10/642,440

N-4-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-N6-(4-dimethylaminomethyl-3-methyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine;

(S)-N6-(4-tert-Butoxymethyl-3-methyl-oxazolidin-2-ylidene)-N4-[3-chloro-4-(3-fluorophenoxyethyl)-phenyl]-quinazoline-4,6-diamine;

(S)-(2-{4-[3-Chloro-4-(3-fluorophenoxyethyl)-phenylamino]-quinazolin-6-ylimino}-3-methyl-oxazolidin-4-yl)-methanol;

(2-{4-[3-Chloro-4-(3-fluorophenoxyethyl)-phenylamino]-quinazolin-6-ylimino}-3-methyl-oxazolidin-5-yl)-methanol;

{3-Methyl-2-[4-(3-methyl-4-phenoxyphenylamino)-quinazolin-6-ylimino]-oxazolidin-5-yl}-methanol;

(2-{4-[3-Chloro-4-(6-methylpyridin-3-yloxy)-phenylamino]-quinazolin-6-ylimino}-3-methyl-oxazolidin-5-yl)-methanol;

N4-(4-Benzenesulfonylphenyl)-N6-(3-methyloxazolidin-2-ylidene)-quinazoline-4,6-diamine;

{2-[4-(4-Benzenesulfonylphenylamino)-quinazolin-6-ylimino]-3-methyl-oxazolidin-5-yl}-methanol;

N4-(4-Benzenesulfonylphenyl)-N6-(3-cyclopropyloxazolidin-2-ylidene)-quinazoline-4,6-diamine;

N6-(Dimethylhexahydropyrrrolo[3,4-d]oxazol-2-ylidene)-N4-(3-methyl-4-phenoxyphenyl)-quinazoline-4,6-diamine;

N4-[3-Chloro-4-(thiazol-2-ylmethoxy)-phenyl]-N6-(3-methyloxazolidin-2-ylidene)-quinazoline-4,6-diamine;


N4-[3-Chloro-4-(pyridin-2-ylmethoxy)-phenyl]-N6-(dimethyl-3-oxa-1,8-diaza-spiro[4.5]dec-2-ylidene)-quinazoline-4,6-diamine;

[2-{4-[3-Chloro-4-(3-fluorobenzyloxy)-phenylamino]-quinazolin-6-ylimino}-3-(2,2,2-trifluoroethyl)-oxazolidin-5-yl]-methanol; and

N4-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-N6-(1-methylpyrrolidin-2-ylidene)-quinazoline-4,6-diamine.

Application 10/642,440








Claim 37 (Currently Amended): A compound including resolved enantiomers, diastereomers and pharmaceutically acceptable salts thereof, said compound comprising having a structure of Formula I:



or resolved enantiomers, diastereomers or pharmaceutically acceptable salts thereof,
wherein

X is N;

R^1 is selected from the structures:



R^2 is hydrogen or a substituted or unsubstituted C_{1-8} alkyl;


Application 10/642,440

SO_2R^5 where each of the above alkyl, alkenyl, alkynyl, cycloalkyl and aryl and heteroaryl portion of R^3 is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, $\text{NR}^4\text{SO}_2\text{R}^5$, $\text{SO}_2\text{NR}^6\text{R}^4$, $\text{C}(\text{O})\text{R}^6$, $\text{C}(\text{O})\text{OR}^6$, $\text{-OC}(\text{O})\text{R}^6$, $\text{NR}^4\text{C}(\text{O})\text{OR}^5$, $\text{NR}^4\text{C}(\text{O})\text{CR}^6$, $\text{C}(\text{O})\text{NR}^4\text{R}^6$, $\text{-NR}^4\text{R}^6$, $\text{NR}^4\text{C}(\text{O})\text{NR}^4\text{R}^6$, $\text{NR}^4\text{C}(\text{NCN})\text{NR}^4\text{R}^6$, -OR^6 , $\text{S}(\text{O})\text{R}^5$, SO_2R^5 aryl and arylalkyl heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;

A is $-(\text{U})_n\text{Z}$, where

n is 0; and

Z is selected from the following structures:



Claim 38: (Canceled).

Claim 39 (Currently Amended): The compound of claim 37, wherein R^2 is hydrogen.Claim 40 (Currently Amended): The compound of claim 37, wherein R^3 is hydrogen.